SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
doi 10.2147/vhrm.s83088
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited


Related search